In future studies, we will further explore the effects of combinations of HIF-1α inhibitors, eIF5A2 inhibitors, and autophagy inhibitors together with cisplatin in patients with NSCLC. This evidence concerns the gene EIF5A2 and non-small cell lung carcinoma.